Informations générales (source: ClinicalTrials.gov)
INSTIGO Trial: Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse in Triple Negative Breast Cancer Patients (INSTIGO)
Observational
Centre Jean Perrin (Voir sur ClinicalTrials)
novembre 2020
novembre 2029
24 mai 2025
The INSTIGO study aims to assess a plasma protein profile at different stages of patient
follow-up as a predictive factor of metastatic recurrence in triple negative breast
cancer. It also aims to look at other potential biomarkers of metastatic relapse such as
Tumor-infiltrating Lymphocytes, circulating tumor DNA, figurative elements in blood, or a
tumor RNA signature.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Centre Jean PERRIN - 63011 - Clermont-Ferrand - France | Hugo VEYSSIERE | Contact (sur clinicalTrials) | |||
Critères
Femme
Inclusion Criteria:
- Female
- Age > 18 years
- Diagnosed with primitive, non-metastatic, histologically proved, triple negative
breast cancer
- Patient able to understand the French language
- Patient affiliated to social security
- Obtaining signed written consent
- Female
- Age > 18 years
- Diagnosed with primitive, non-metastatic, histologically proved, triple negative
breast cancer
- Patient able to understand the French language
- Patient affiliated to social security
- Obtaining signed written consent
- Persons deprived of their freedom or under guardianship or incapable of giving
consent
- Refusal to participate